Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilberto Lopes

Showing results (111-120 of 177) with videos related to

Pageof 18
Sort By:
Cancer Medicine|July 31, 2025
Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real-World Evidence ApproachLeonardo Rojas, Natalia Sánchez, Jorge Ceballos, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2014
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTereHeloisa P Soares, Soley Bayraktar, Marcelo Blaya, et al.
Eclinicalmedicine|February 19, 2025
Evolving trends in lung cancer risk factors in the ten most populous countries: an analysis of data from the 2019 Global Burden of Disease StudyChinmay T Jani, Samuel A Kareff, Dan Morgenstern-Kaplan, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2006
Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC)Luis E Raez, Edgardo S Santos, Gilberto Lopes, et al.
Cancer Medicine|February 23, 2021
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysisJayson L Parker, Sebnem S Kuzulugil, Kirill Pereverzev, et al.
Breast (Edinburgh, Scotland)|November 26, 2025
Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 9)Alexandru Eniu, Runcie C W Chidebe, Peter Vuylsteke, et al.
JAMA Network Open|December 5, 2023
Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIVDaniel S O'Neil, Yehoda M Martei, Katherine D Crew, et al.
Cancer Treatment and Research Communications|April 30, 2026
The genomic, transcriptomic, and immunologic landscape of TEM8 (ANTXR1) in neuroendocrine neoplasms (NENs) including small-cell lung cancer (SCLC)Samuel A Kareff, Harris Krause, Andrew Elliott, et al.
Lung Cancer (Amsterdam, Netherlands)|April 17, 2018
The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatmentsLuis E Raez, Andrés F Cardona, Edgardo S Santos, et al.
Journal of the National Cancer Institute|January 27, 2021
The Global Landscape of Treatment Standards for Breast CancerDario Trapani, Jean Yves Douillard, Eric P Winer, et al.
Pageof 18

Showing results (111-120 of 177) with videos related to

Sort By:
Pageof 18
Cancer Medicine|July 31, 2025
Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real-World Evidence ApproachLeonardo Rojas, Natalia Sánchez, Jorge Ceballos, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2014
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTereHeloisa P Soares, Soley Bayraktar, Marcelo Blaya, et al.
Eclinicalmedicine|February 19, 2025
Evolving trends in lung cancer risk factors in the ten most populous countries: an analysis of data from the 2019 Global Burden of Disease StudyChinmay T Jani, Samuel A Kareff, Dan Morgenstern-Kaplan, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2006
Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC)Luis E Raez, Edgardo S Santos, Gilberto Lopes, et al.
Cancer Medicine|February 23, 2021
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysisJayson L Parker, Sebnem S Kuzulugil, Kirill Pereverzev, et al.
Breast (Edinburgh, Scotland)|November 26, 2025
Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 9)Alexandru Eniu, Runcie C W Chidebe, Peter Vuylsteke, et al.
JAMA Network Open|December 5, 2023
Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIVDaniel S O'Neil, Yehoda M Martei, Katherine D Crew, et al.
Cancer Treatment and Research Communications|April 30, 2026
The genomic, transcriptomic, and immunologic landscape of TEM8 (ANTXR1) in neuroendocrine neoplasms (NENs) including small-cell lung cancer (SCLC)Samuel A Kareff, Harris Krause, Andrew Elliott, et al.
Lung Cancer (Amsterdam, Netherlands)|April 17, 2018
The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatmentsLuis E Raez, Andrés F Cardona, Edgardo S Santos, et al.
Journal of the National Cancer Institute|January 27, 2021
The Global Landscape of Treatment Standards for Breast CancerDario Trapani, Jean Yves Douillard, Eric P Winer, et al.
Pageof 18